%0 Journal Article %A Clair Vandersteen %A Magali Payne %A Louise-Émilie Dumas %A Élisa Cancian %A Alexandra Plonka %A Grégoire D’Andrea %A David Chirio %A Élisa Demonchy %A Karine Risso %A Florence Askenazy-Gittard %A Charles Savoldelli %A Nicolas Guevara %A Philippe Robert %A Laurent Castillo %A Valeria Manera %A Auriane Gros %T OLFACTORY TRAINING EFFICIENCY IN POST-COVID-19 PERSISTENT OLFACTORY DISORDERS %D 2022 %R 10.1101/2022.02.27.22271572 %J medRxiv %P 2022.02.27.22271572 %X Background Persistent post-viral olfactory disorders (PPVOD) are widely reported after a COVID-19 and estimate to 30% one year after infection. Parosmias are the main qualitative dysosmia associated with olfaction recovery. No treatment is, to date, significantly efficient on PPVOD except olfactory training (OT). The main objective of this work was to evaluate OT efficiency on post-COVID-19 PPVOD.Methods Consecutive patients consulting to the ENT department with post-COVID-19 PPVOD were included after mainly clinical examination, the complete Sniffin’ Stick Test (TDI), the short version of the Questionnaire of olfactory disorders and the SF-36. Patients were trained to practice a self-olfactory training (professional manufactured olfactory training kit) twice a day for 6 months before coming back and undergo the same complete evaluation.Results Forty-three patients were included and performed 3,5 months of OT in average. There was a significant improvement in the mean TDI score increasing from 24,7 (±8,9) before the OT to 30,9 (±9,8) (p<0,001). Parosmias increased significantly from 8 (18,6%) to 27 (62.8%) (p<0,001). Based on normative data divided by sex and age, a significant increase in the number of normosmic participants was only found for the Threshold values (p<0,001). Specific and general olfaction-related quality of life improved after the OT.Conclusions OT seems to be efficient in post-COVID-19 PPVOD, probably on the peripheral regenerative part of the olfactory recovery. Future therapeutic strategies may focus on the central aspects of the post-COVID-19 PPVOD.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04799977Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board of the Nice University Hospital (CNIL number: 412) and registered with a ClinicalTrials.gov number (ID: NCT04799977).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors %U https://www.medrxiv.org/content/medrxiv/early/2022/02/28/2022.02.27.22271572.full.pdf